Amgen Inc.

Hongyu Liao

Nuria A Tamayo

Mark Henry Norman

Shon Booker

Longbin Liu

Markian Myroslaw Stec

Fang-Tsao Hong

Yunxin Y Bo

Seifu Tadesse

Celia Dominguez

Ning Chen

Bin Wu

Anthony B Reed

Nobuko Nishimura

Kevin Chao Yang

Victor J Cee

Liping H Pettus

Brian Alan Lanman

Dawei Zhang

Ryan Paul Wurz

Xianghong Wang

Daniel La

Russell Graceffa

Alan C Cheng

Tae-Seong Kim

Alessandro Boezio

Deborah Choquette

Adrian Leonard Smith

Michele Potashman

Noel D'Angelo

Bradley J Herberich

Kelvin K C Sham

Guo-Qiang Cao

Partha P Chakrabarti

John Stellwagen

Emily Anne Peterson

Hongbing Huang

Claire L M Jackson

Kristin L Andrews

Kurt E Weiler

Martin H Goldberg

Adrian L Smith

Noel D'angelo

Claire L Jackson

Richard Lewis

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

Inhibitors of PI3 kinase and/or mTOR

The present invention relates to imidazopyridazine compounds of Formula I, such as representative structure A, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.

Imidazopyridazine inhibitors of PI3 kinase for cancer treatment

Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Vanilloid receptor ligands and their use in treatments

The present invention relates to compounds having the general formulaor a pharmaceutically acceptable salt thereof, wherein Ris a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein Ris additionally substituted; and Ris a substituted Calkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic &#x3b2; cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

Substituted heterocyclic compounds and methods of use

Growing community of inventors

Thousand Oaks, CA, United States of America

Hongyu Liao